Company Enzo Biochem, Inc.

Equities

ENZ

US2941001024

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Sector Other Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:58 2024-04-25 pm EDT			5-day change	1st Jan Change
1.07 ^USD	+0.94%		-5.31%	-23.02%

Mar. 15	North American Morning Briefing : Inflation Worries Continue to Weigh on Mood	DJ
Mar. 13	Enzo Biochem, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	CI

Enzo Biochem, Inc. is focused on molecular diagnostics and has a portfolio of technical platforms and reagent sets supporting a diverse range of biomedical research and translational science needs. The Company operates through the product segment, which manufactures, develops and markets products and tools for clinical research, translational research, drug development and bioscience research customers worldwide. The Company is engaged in product development and manufactures and supplies a comprehensive portfolio of products, including antibodies, genomic probes, assays, biochemicals and proteins. The Company's products and technologies are used in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry. Its life science division supports the work of research centers and industry partners. It has built a portfolio of intellectual property assets, comprised of around 457 owned patents worldwide.

Number of employees: 185

USD in Million	2022	Weight	2023	Weight	Delta
Life Sciences Products 100.0 %	33	30.5 %	31	100.0 %	-4.85%

USD in Million	2022	Weight	2023	Weight	Delta
United States 59.7 %	94	88.0 %	19	59.7 %	-80.31%
Europe 27.2 %	9	8.0 %	8	27.2 %	-1.40%
Asia Pacific 13.1 %	4	4.0 %	4	13.1 %	-5.40%

Managers	Title	Age	Since
Kara Cannon CEO	Chief Executive Officer	56	10-12-31
Elazar Rabbani FOU	Founder	81	76-07-31
Patricia Eckert DFI	Director of Finance/CFO	47	-
Dieter Schapfel CTO	Chief Tech/Sci/R&D Officer	60	14-06-30

Members of the board	Title	Age	Since
Steven Pully CHM	Chairman	64	23-10-25
Mary Tagliaferri BRD	Director/Board Member	58	20-11-16
Bradley Radoff BRD	Director/Board Member	50	22-01-02
Elazar Rabbani FOU	Founder	81	76-07-31
Kara Cannon CEO	Chief Executive Officer	56	10-12-31
Ian Walters BRD	Director/Board Member	57	20-11-24

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	51,225,734	38,832,766 ( 75.81 %)	0	75.81 %

Name	Equities	%	Valuation
Harbert Fund Advisors, Inc. 10.10 %	5,175,913	10.10 %	7 M $
James Wolf 9.648 %	4,942,400	9.648 %	6 M $
Bradley Radoff 9.411 %	4,820,882	9.411 %	6 M $
1 Main Capital Management LLC 4.880 %	2,500,000	4.880 %	3 M $
Renaissance Technologies LLC 4.840 %	2,479,195	4.840 %	3 M $
Elazar Rabbani 3.840 %	1,966,998	3.840 %	2 M $
Vanguard Global Advisers LLC 3.663 %	1,876,622	3.663 %	2 M $
Tang Capital Management LLC 3.319 %	1,700,000	3.319 %	2 M $
Potomac Capital Management, Inc. 2.893 %	1,481,742	2.893 %	2 M $
American Investors Advisors, Inc. 2.374 %	1,216,196	2.374 %	2 M $

Enzo Biochem, Inc.

81 Executive Boulevard Suite 3

10022, New York

+631 755 5500

http://www.enzo.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
ENZO BIOCHEM, INC.	-24.82%	54.3M
IQVIA HOLDINGS INC.	+1.03%	43.84B
MODERNA, INC.	+6.29%	41.68B
LONZA GROUP AG	+45.26%	41.25B
CELLTRION, INC.	-11.96%	27.04B
ICON PUBLIC LIMITED COMPANY	+6.76%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.63%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.82%	12.29B
MEDPACE HOLDINGS, INC.	+26.10%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.13%	11.15B

Other Biotechnology & Medical Research